Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company will next seek approval from the U.S. Food and Drug ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Please watch the video at Investors.com - How To Buy Stocks: IBD's Four ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...